Most cryptocurrency sectors rise, BTC surpasses $78,000, NFT sector rises for three consecutive days
Foresight News reports, according to SoSoValue data, most sectors of the crypto market have risen, with the NFT sector performing particularly well, surging for three consecutive days and increasing by 2.63% in the past 24 hours. Among them, Pudgy Penguins (PENGU) rose by 8.88%, Blur (BLUR) rose by 8.32%, Audiera (BEAT) and Zora (ZORA) increased by 3.17% and 3.64% respectively. Meanwhile, Bitcoin (BTC) rose by 2.76%, breaking through $78,000; Ethereum (ETH) increased by 2.09%, approaching $2,400.
For other sectors, the Layer2 sector increased by 1.14% in 24 hours, with Starknet (STRK) up 18.56%; the Meme sector rose by 1.12%, with SPX6900 (SPX) up 14.87%; the DeFi sector climbed 0.85%, with Genius (GENIUS) gaining 16.71%; CeFi sector increased by 0.83%, with Bitget Token (BGB) up 3.08%; the Layer1 sector rose by 0.58%, with Canton Network (CC) up 2.65%; the PayFi sector fell by 0.24%, but Ultima (ULTIMA) was up 5.94%. The crypto sector index reflecting the sector's historical performance shows that ssiRWA, ssiNFT, and ssiLayer1 indices rose by 3.72%, 3.36%, and 1.55% respectively.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
